NOVARTIS

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.

The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.

FDA grants full approval to Travere Therapeutics’ Filspari (sparsentan) for slowing kidney function decline in adults with primary IgA nephropathy (IgAN), supported by phase 3 PROTECT study results showing significant kidney function preservation over two years compared to irbesartan.

JuneBrain secures $300,000 grant from MDIC to modernize its quality management system, partnering with Compliance Group and Siemens to implement Siemens’ Polarion technology, aiming for FDA clearance and enhanced patient safety.

AAVantgarde Bio appoints Jayashree Sahni, MD, FRCOphth, EMBA as Chief Medical Officer, bringing over 25 years of ophthalmology and drug development experience. Sahni will lead gene therapy programs for inherited retinal disorders, leveraging AAVantgarde's two AAV vector platforms for large gene delivery.

ESMO 2024 in Barcelona will feature discussions on cancer therapeutics, including anticipated presentations on bispecific antibodies and anti-TIGIT therapies. Other topics include radioligand therapies and synthetic lethality assets. Experts are optimistic about the potential of these therapeutic classes, despite past challenges.

The Orphan Drugs Market is projected to grow from USD 225.9 Billion in 2023 to USD 493.21 Billion by 2031, driven by rising prevalence of rare diseases, unmet medical needs, favorable regulatory policies, technological advancements, and growing public and patient advocacy. Key challenges include high R&D costs, limited patient populations, pricing and reimbursement issues, and lack of long-term data. Trends include focus on gene therapies, personalized medicine, stakeholder collaboration, and expansion into emerging markets. North America leads the market, followed by Europe and Asia Pacific.

Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.

Atrasentan hydrochloride expected to generate $376 mn by 2033 in the US. The drug, under development for immunoglobulin A nephropathy and proteinuric glomerular diseases, uses a risk-adjusted NPV model (rNPV) to account for development risks. Novartis, a healthcare company focusing on drug discovery and marketing, reported revenues of $46,660 mn in FY2023, with an operating margin of 20.5%.

Iscalimab's revenue in the US is projected to reach $92 mn by 2038. The drug, an anti-CD40 monoclonal antibody, is under development for various conditions including type 1 diabetes and myasthenia gravis. Novartis, the developer, reported FY2023 revenues of $46,660 mn, with a net margin of 31.8%. A risk-adjusted NPV model (rNPV) for Iscalimab, considering R&D costs and approval likelihood, is available for purchase.